Shares of ArQule Inc. of Woburn continued to slide after the company on Friday said a study showed the combined use of its lead drug candidate with two other cancer-fighting treatments did not meet survival targets for patients with a certain type of colorectal cancer. ArQule is engaged in the development of next-generation, small-molecule cancer therapeutics. Its products and research programs focus on key biological processes that are central to human cancers.
ArQule slides again after study disappoints
January 15, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢